A large body of experimental and clinical evidence implicates overexpression of the urokinase plasminogen activator (uPA) system as a modulator of the aggressive behaviour of cancer cells and as a strong prognostic factor for predicting poor breast cancer patient outcome (Pollanen et al, 1991; Andreasen et al, 1997; Schmitt et al, 2000). This evidence concerns the gene PLAU and breast carcinoma.